OBJECTIVES: The purpose of this study was to demonstrate the costs of hospitalization and procedures as a result of the progression of these diseases when not properly managed with prophylactic drug treatment as out-of-pocket expenses. METHODS: An administrative claims database containing over 18 million cases was used in a retrospective cohort analysis identifying the costs of medical bills from hospitalizations for revascularization and angioplasty with stent placement from May to December 2014. Subsequently, these patients were separated in 3 groups: Group I – patients with previous history of Acute Myocardial Infarction (ICD I21 and I22); Group II – patients with previous history of diabetes mellitus (ICD E10 to E14); and Group III – patients who do not fit the criteria of the other two groups. RESULTS: Diabetic patients who underwent angioplasty without stent placement cost an average of 24,175.49, diabetic patients who underwent angioplasty with conventional stent placement cost an average of 24,880.76, patients with other ICDs who underwent revascularization cost an average of 29,008.50, diabetic patients who underwent angioplasty with drug-eluting stent placement cost an average of 44,264.36, patients with other ICDs who underwent angioplasty with drug-eluting stent placement cost an average of 47,053.16, patients with acute myocardial infarction who underwent revascularization cost an average of 55,585.20, patients with acute myocardial infarction who underwent revascularization and angioplasty with drug-eluting stent placement cost an average of 57,391.90, and patients with acute myocardial infarction who underwent angioplasty with drug-eluting stent placement cost an average of 58,476.30. CONCLUSIONS: Private health insurances in Brazil provide treatment only for hospitalized patients instead of covering prophylactic drug treatment, a practice that might lead to higher expenditure on hospitalization and procedures for unmanaged cardiovascular diseases, where costs can range from 24,175.49 up to 58,476.30, an increase of 41%.